Other BÜHLMANN Fecal Calprotectin Assays Citations

Wright, E.K. et al., Cost-effectiveness of Crohn’s disease post-operative care, World J Gastroenterol. 2016 Apr 14;22(14):3860-8. doi: 10.3748/wjg.v22.i14.3860.

Shentova, R. et al., 2016, Diagnostic Value of Fecal Calprotectin Point of Care Testing in the Pediatric Practice, Merit Res. J. Med. Med. Sci. Available online http://www.meritresearchjournals.org/mms/index.htm

Gauss, A. et al., Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease, Medicine 2016 Apr;95(16):e3477. doi: 10.1097/MD.0000000000003477.

Brandse, J.F. et al., Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis, Inflamm Bowel Dis. 2016 Jun;22(6):1384-90. doi: 10.1097/MIB.0000000000000746.

Lasson, A. et al., The Intra-Individual Variability of Faecal Calprotectin: A Prospective Study In Patients With Active Ulcerative Colitis, Journal of Crohn’s and Colitis. 015 Jan;9(1):26-32. doi: 10.1016/j.crohns.2014.06.002.

Yamamato, T., The clinical value of fecal calprotectin and lactoferrin measurement in postoperative Crohn’s disease, United European Gastroenterology Journal. 2015 Feb;3(1):5-10. doi: 10.1177/2050640614558106.

Pavlidis, P. et al., Faecal calprotectin identifies non responders to anti-TNFα therapy when measured after induction in inflammatory Crohn’s disease, Poster King’s College, NHS.

Lin, Wei-Chen et al., Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients, World J Gastroenterol. 2015 Dec 28;21(48):13566-73. doi: 10.3748/wjg.v21.i48.13566.

Kristensen, V. et al., Prediction of Endoscopic Disease Activity in Ulcerative Colitis by Two Different Assays for Fecal Calprotectin, Journal of Crohn’s and Colitis. 2015 Feb;9(2):164-9. DOI: 10.1093/ecco-jcc/jju015

Hosseini, S.V. et al., Fecal Calprotectin is an Accurate Tool and Correlated to SEO Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis, Iran Red Crescent Med J. 2015 Feb 21;17(2):e22796. DOI:10.5812/ircmj.22796

Ferreiro-Iglesias, R. et al., Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn’s disease patients on maintenance treatment with adalimumab, Scandinavian Journal of Gastroenterology. 2016;51(4):442-7. DOI:10.3109/00365521.2015.1115546

Bin-Nun, A. et al., Rapid Fecal Calprotectin (FC) Analysis: Point of Care Testing for Diagnosing Early Necrotizing Enterocolitis, Am J Perinatol. 2015 Mar;32(4):337-42. DOI:10.1055/s-0034-1384640

Calafat, M. et al., High Within-day Variability of Fecal Calprotectin Levels in Patients with Active Ulcerative Colitis: What Is the Best Timing for Stool Sampling? Inflamm Bowel Dis. 2015 May;21(5):1072-6. DOI: 10.1097/MIB.0000000000000349.

Wang, S. et al., Faecal calprotectin concentrations in gastrointestinal diseases, Journal of International Medical Research. 2013 Aug;41(4):1357-61. DOI:10.1177/0300060513488499.

Oord, T. and Hornung, N., Fecal calprotectin in healthy children, Scandinavian Journal of Clinical & Laboratory Investigation. 2014 Apr;74(3):254-8. DOI:10.3109/00365513.2013.879732.

Li, F. et al., Comparison of the different kinds of feeding on the level of fecal calprotectin, Early Human Development. 2014 Sep;90(9):471-5. DOI:10.1016/j.earlhumdev.2014.06.005.

Levine, A. et al., Comparison of Outcomes Parameters for Induction of Remission in New Onset Pediatric Crohn’s Disease: Evaluation of the Porto IBD Group “Growth Relapse and Outcomes with Therapy” (GROWTH CD) Study, Inflamm Bowel Dis. 2014 Feb;20(2):278-85. DOI: 10.1097/01.MIB.0000437735.11953.68.

Dhaliwal, A. et al., Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterology. 2015;6:14-19 doi:10.1136/flgastro-2013-100420.

Chang, M. et al., Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome, Molecular Medicine Reports. 2014 Jul;10(1):522-6. DOI: 10.3892/mmr.2014.2180.

Burri, E. et al, Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness, BMC Gastroenterology. y 2014, 14:57. DOI: 10.1186/1471-230X-14-57.

Rogler, G. et al., Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: Expert clinical opinion, Journal of Crohn’s and Colitis. 2013 Sep;7(8):670-7. DOI:10.1016/j.crohns.2013.02.014.

Paul, S. et al., Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study, Inflamm Bowel Dis. 2013 Nov;19(12):2568-76.  DOI:10.1097/MIB.0b013e3182a77b41.

Whitehead, S.J. et al., Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits, Ann Clin Biochem. 2013 Jan;50(Pt 1):53-61. DOI:10.1258/acb.2012.011272.

Kok, L. et al. Diagnostic Accuracy of Point-of-Care Fecal Calprotectin and Immunochemical Occult Blood Tests for Diagnosis of Organic Bowel Disease in Primary Care: The Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) Study, Clinical Chemistry. 2012 Jun;58(6):989-98.  DOI: 10.1373/clinchem.2011.177980.

Hessels, J. et al. Evaluation of Prevent ID and Quantum Blue rapid tests for fecal calprotectin, Clin Chem Lab Med. 2012 Jan 13;50(6):1079-82. DOI:10.1515/cclm-2011-0855.

Kolho, K. et al. Rapid Test for Fecal Calprotectin Levels in Children With Crohn Disease, JPGN. 2012 Oct;55(4):436-9. DOI:10.1097/MPG.0b013e318253cff1.

Vermunt, R. et al., 2011, Calprotectin in biomarker-mediated drug development: Method validation for the quantification of fecal Calprotectin, eurofins poster.